{"id":202,"date":"2025-05-29T12:44:09","date_gmt":"2025-05-29T12:44:09","guid":{"rendered":"https:\/\/cryptoinvestmentinsight.com\/index.php\/2025\/05\/29\/hhs-slams-under-tested-mrna-technology-as-trump-cuts-modernas-vaccine-funding\/"},"modified":"2025-05-29T12:44:09","modified_gmt":"2025-05-29T12:44:09","slug":"hhs-slams-under-tested-mrna-technology-as-trump-cuts-modernas-vaccine-funding","status":"publish","type":"post","link":"https:\/\/cryptoinvestmentinsight.com\/index.php\/2025\/05\/29\/hhs-slams-under-tested-mrna-technology-as-trump-cuts-modernas-vaccine-funding\/","title":{"rendered":"HHS slams \u2018under-tested\u2019 mRNA technology as Trump cuts Moderna\u2019s vaccine funding"},"content":{"rendered":"<p class=\"speakable\">President Donald Trump&#8217;s Department of Health and Human Services (HHS) is terminating awards totaling more than $750 million dollars that were provided to pharmaceutical manufacturer Moderna to help facilitate its production of mRNA-based bird flu vaccines.&nbsp;<\/p>\n<p class=\"speakable\">During President Joe Biden&#8217;s final week in office, his administration awarded $590 million to Moderna to help speed up its production of mRNA-based vaccines. The $590 million award followed a separate $176 million award Biden gave to Moderna earlier last year for mRNA vaccine technology.<\/p>\n<p>Messenger RNA vaccines are a newer type of vaccine technology, which was utilized by companies like Moderna and Pfizer to develop their COVID-19 vaccines. The vaccine technology was at the center of a lot of criticism amid the coronavirus pandemic for potentially being associated with adverse side effects in some people who took them, such as myocarditis.<\/p>\n<\/p>\n<p>Trump administration officials previously hinted at the potential that this funding could be terminated, citing a lack of oversight during the Biden administration pertaining to vaccine production.&nbsp;<\/p>\n<p>&#8216;After a rigorous review, we concluded that continued investment in Moderna\u2019s H5N1 mRNA vaccine was not scientifically or ethically justifiable,&#8217; HHS Communications Director Andrew Nixon said. &#8216;This is not simply about efficacy \u2014 it\u2019s about safety, integrity, and trust. The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public.&#8217;<\/p>\n<\/p>\n<p>The announcement reflects a larger shift in federal vaccine priorities, after HHS Secretary Robert F. Kennedy Jr. announced earlier this week that COVID-19 vaccines would be removed from the federal government&#8217;s list of recommended vaccines for children and pregnant women.&nbsp;<\/p>\n<p>Meanwhile, a report from Senate Republicans released earlier this month suggested the Biden administration withheld critical safety data and downplayed known risks tied to the mRNA COVID-19 vaccine. In particular, the Senate report focuses on HHS\u2019 awareness of, and response to, cases of myocarditis \u2014 a type of heart inflammation \u2014 following COVID-19 vaccination.<\/p>\n<p>&#8216;Rather than provide the public and health care providers with immediate and transparent information regarding the risk of myocarditis following mRNA COVID-19 vaccination, the Biden administration waited until late June 2021 to announce changes to the labels for the Moderna and Pfizer COVID-19 vaccines based on the \u2018suggested increased risks\u2019 of myocarditis and pericarditis,&#8217; the Senate report states. &#8216;Even though CDC and FDA officials were well aware of the risk of myocarditis following COVID-19 vaccination, the Biden administration opted to withhold issuing a formal warning to the public for months about the safety concerns, jeopardizing the health of young Americans.&#8217;<\/p>\n<p>In response to the Trump administration&#8217;s funding termination, Moderna put out a press release acknowledging the move, but also touting the &#8216;safety profile&#8217; observed amid its work on a new mRNA bird flu vaccine.<\/p>\n<p>&#8216;While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1\/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,&#8217; said St\u00e9phane Bancel, Chief Executive Officer of Moderna. &#8216;These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.&#8217;<\/p>\n<p><i>Fox News Digital&#8217;s Brooke Singman contributed to this report.<\/i><\/p>\n<\/p>\n<div>This post appeared first on FOX NEWS<\/div>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>President Donald Trump&#8217;s Department of Health and Human Services (HHS) is terminating awards totaling more than $750 million dollars that were provided to pharmaceutical manufacturer Moderna to help facilitate its production of mRNA-based bird flu vaccines.&nbsp; During President Joe Biden&#8217;s final week in office, his administration awarded $590 million to Moderna to help speed up&hellip;<\/p>\n","protected":false},"author":1,"featured_media":203,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/posts\/202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/comments?post=202"}],"version-history":[{"count":0,"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/posts\/202\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/media\/203"}],"wp:attachment":[{"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/media?parent=202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/categories?post=202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cryptoinvestmentinsight.com\/index.php\/wp-json\/wp\/v2\/tags?post=202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}